维普期刊资源整合服务平台（V6.5）

68篇 您的检索式：作者名="Muggia FM"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Overview of cancer-related hypercalcemia: epi- dermiologyand etiology显示文摘	Muggia FM	1990	Semin Onco11990，17，25：	1
2	PhaseⅢrandomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stageⅢorⅣovarian cancer:a gynecologic oncology group study显示文摘	Muggia FM Braly PS Brady MF	2000	J Clin Oncol2000，18，1：	1
3	Phase I and pharrnacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine 显示文摘	Muggia FM Chan KK Russell C	1991	Cancer Chemother Pharmacol1991，28，：	1
4	Cisplatin update显示文摘	Muggia FM	1991	Semin Oncol1991，18，：	1
5	Overview of cancer-related hypercalcemia : epidemiology and etiology 显示文摘	Muggia FM	1990	Semin Oncol1990，17，25：	1
6	Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel:an in vitro study显示文摘	Szebeni J Muggia FM Alving CR	1998	J Natl Cancer Ins1998，90，4：	1
7	Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: An in Vitro Study 显示文摘	Szebeni J Muggia FM Alving CR	1998	Journal of The National Cancer Institute1998，90，4：	1
8	Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study 显示文摘	Szebeni J Muggia FM Alving CR	1998	J Natl Cancer Inst1998，90，4：	1
9	Paclitaxe 13 - hourinfusion given alone and combined with Carboplatin:Preliminary results of dose - escalation trials显示文摘	Muggia FM Vafai D Natale R	1995	Semin Oncol1995，22，9：	1
10	Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel:An in vitro study显示文摘	Szebeni J Muggia FM Alving CR	1998	J Natl Cancer Inst1998，90，4：	1
11	Phase study of liposomal doxorubicin in refractor ovarian cancer : antitumor activity and toxicity modification by liposomai encapsulation 显示文摘	Muggia FM Hainsworth JD Jeffers S	1997	J Clin Oncol1997，15，3：	1
12	Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel:an in vitro study显示文摘	Szebeni J Muggia FM Alving CR	1998	J Natl Cancer Inst1998，90，4：	1
13	Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer; a gynecologic oncology group study显示文摘	Muggia FM Braly PS Brady MF etal	2000	J Clin Oncol2000，18，1：	1
14	PhaseⅡstudy of liposomal doxorubicin in refractory ovarian cancer:antitumor activity and toxicity modification by liposomal encapsulation显示文摘	Muggia FM Hainsworth JD Jeffers S	1997	J Clin Oncol1997，15，3：	1
15	Complement activation by Cremophor ELas a possible contributor to hypersensitivity to paclitaxel:An in vitro study显示文摘	Szebeni J Muggia FM Alving CR	1998	J Natl Cancer Inst1998，90，4：	1
16	Overview of cancer-related hypercalcemia: epide- miology and etiology 显示文摘	Muggia FM	1990	Semin Oncol1990，17，25：	1
17	Overview of cancer--related hyperealcemia: epidermiologyand etiology显示文摘	Muggia FM	2006	Semin Onco2006，17，25：	1
18	Complement activation by Cremophor ELas a possible contributor to hypersensitivity显示文摘	Szebeni J Muggia FM	1998	J Natl CancerInst1998，90，4：	1
19	Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ and Ⅳ ovarian cancer:a Gynecologic Oncology Group study显示文摘	Muggia FM Braly PS Brady MJ	2000	J Clin Oncol2000，18，：	1
20	Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer显示文摘	Muggia FM	2004	Semin Onco12004，31，615：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示